+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Predictors of transfusion in acute myocardial infarction: Insights from APEX-AMI (Assessment of pexelizumab in acute myocardial infarction) trial



Predictors of transfusion in acute myocardial infarction: Insights from APEX-AMI (Assessment of pexelizumab in acute myocardial infarction) trial








Accession: 021585510

Download citation: RISBibTeXText


Related references

Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. American Heart Journal 160(4): 671-677, 2010

ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Circulation 118(13): 1335-1346, 2008

Aborted myocardial infarction after primary percutaneous coronary intervention: magnetic resonance imaging insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal 165(2): 226-233, 2013

Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal 159(5): 899-904, 2010

Pexelizumab fails to inhibit assembly of the terminal complement complex in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Insight from a substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. American Heart Journal 164(6): E19; Author Reply E21, 2012

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. American Heart Journal 149(3): 402-407, 2005

Contribution of angiographic and electrocardiographic parameters of reperfusion to prediction of mortality and morbidity after acute ST-elevation myocardial infarction: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. American Heart Journal 158(5): 755-760, 2009

Do baseline atrial electrocardiographic and infarction patterns predict new-onset atrial fibrillation after ST-elevation myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Journal of Electrocardiology 43(4): 351-358, 2010

Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. American Heart Journal 160(2): 272-278, 2010

Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. American Heart Journal 163(5): 797-803, 2012

A model for predicting mortality in acute ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: results from the Assessment of Pexelizumab in Acute Myocardial Infarction Trial. Circulation. Cardiovascular Interventions 3(5): 414-422, 2010

Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction Insights from the complement inhibition in myocardial infarction treated with angioplasty Trial. Journal of the American College of Cardiology 43(5 Suppl. A): 287A, 2004

Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. Contemporary Clinical Trials 32(2): 178-187, 2011

Efficient adjudication of endpoints in an international trial: Strategic lessons from the clinical events committee (CEC) of the assessment of pexelizumab in acute myocardial infarction (APEX AMI) trial. 2007

Mortality implications of primary percutaneous coronary intervention treatment delays: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction trial. Circulation. Cardiovascular Quality and Outcomes 4(2): 183-192, 2011